• Home
  • About Us
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Technology
  • Product Pipeline
    • Cancer Tests
    • Pharma Support
  • News & Information
    • News
    • Publications
  • Contact Us
  • Home
  • About Us
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Technology
  • Product Pipeline
    • Cancer Tests
    • Pharma Support
  • News & Information
    • News
    • Publications
  • Contact Us

Science in Genomic Medicine

  • Posted by nir_admin
  • On February 12, 2017
  • 0 Comments
  • clinic, genomics, science

With the launch of the precision medicine cohort initiative, All of UsSM  Research Program, the importance of incorporating implementation science in genomic medicine is greater than ever to ensure population health benefits for all. Historically, the speed of genomic discovery has far exceeded the time required to put these potentially life-saving medical discoveries into practice. In December 2016, the Annual Conference on the Science of Dissemination and Implementation held a session on implementation science in genomic medicine. This session and our recently published systematic review demonstrated a need for more implementation science research in genomic medicine to realize the promise of precision medicine for all.

In the systematic review, we studied the extent that implementation science approaches are being applied to medical genomics research by examining all translational genomics research articles identified through the CDC’s Public Health Genomics Knowledge Base in 2014. Of the 626 translational genomics studies, 283 included components of implementation research, and from those, we identified four major gaps in the current genomic medicine literature.

  1. There is a need to incorporate rigorous implementation science methods that are grounded in theory into genomic medicine research. Less than 2% of identified articles incorporated implementation science frameworks or theories. Perhaps as a result, studies often neglected the measurement of contextual factors that drive implementation. The unit of analysis in >98% of published studies were the individual, rather than the provider or health system. Incorporating multilevel contextual factors will be essential in understanding how to effectively implement genomic medicine into clinical and community health settings.
  2. Implementation research in genomic medicine must move into more diverse settings and populations in order to improve population health and reduce health inequities. The majority of published studies occurred within an academic medical center setting. Fewer than half of the included studies reported race/ethnicity data, challenging our ability to assess racial/ethnic disparities and the generalizability of study findings across subpopulations. In addition, the majority of studies were in oncology, likely reflecting the current evidence base in the field. However, as evidence accrues, research in other disease areas will be needed.
  3. Most studies were observational, many reporting barriers and facilitators for genomic medicine implementation. The time is ripe to move beyond observational study designs and to begin testing evidence-based implementation strategies to optimize genomic medicine.
  4. Few studies reported the use of collaborative processes (e.g., key stakeholders) and sustainability indicators (e.g., monetary and non-monetary costs, workforce needs, infrastructure). By incorporating more collaborative processes, we can aid successful implementation of genomic medicine.

Accounting for these four areas, we need to conduct more robust research that facilitates the implementation in genomic medicine to improve population health. With the momentum behind the PMI, now is the time to build an implementation science foundation to reap the benefits of genomics and precision medicine.

 3

0 Comments

Leave Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts
  • Orbit Genomics strengthens its Board of Directors with the appointment of Morten Søgaard, PhD
  • Orbit Genomics is thrilled to be part of 18 companies selected from more than 850 applicants for to Plug and Play’s Health Batch 9
  • Orbit Genomics is presenting at the Rocky Mountain Life Science Investor and Partnering Conference on Sep 5
  • Orbit Genomics is recognized by MedTech Innovator as one of the 50 best-in-class startups in the medtech industry.
  • CSO, Skip Garner, in the News
Recent Comments
    Archives
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • August 2017
    • February 2017

    Microsatellite Genotyping in Lung Cancer

    Next thumb
    Scroll
    Quick Links
    • Home
    • About Us
    • Contact
    Information
    • Science & Technology
    • Product Pipeline
    • News & Information
    Contact

    menu_dot Phone:
         720-515-0395

    menu_dot Email:
         info@orbitgenomics.com

         Social Media

         Facebook  Twitter  Linkedin

    Ventac Partners
    ventac-partners

    @2017 OrbitGenetics.com - Powered by wprezz.com

    WordPress Web Design by Simplio_Web_Studio_logo